The Randox TxBCardio assay allows response to aspirin therapy to be tested on automated clinical chemistry analysers in the laboratory, without the need for any additional, dedicated equipment. Randox TxBCardio offers an efficient option for the evaluation of aspirin therapy effectiveness in as little as ten minutes.
The primary target of aspirin therapy is TxA₂, however this has a very short half-life which makes accurate measurement problematic. When TxA₂ degrades it is converted into a number of metabolites, the most abundant of which is 11dhTxB₂. RandoxTxBCardio specifically measures the 11dhTxB₂ metabolite and therefore offers a highly accurate method for the analysis of TxA₂ production in patients.
The Randox TxBCardio assay has applications available for an extensive range of clinical chemistry analysers, liquid ready-to-use format and complementary controls and calibrators available